Article Text

Download PDFPDF
CBD diagnostic criteria: exclusions as important as inclusions
  1. Irene Litvan1,
  2. Anthony E Lang2,3,
  3. Melissa Armstrong4
  1. 1Neuroscience Department, University of California San Diego, La Jolla, California, USA
  2. 2Neurology, Toronto Western Hospital Krembil Neuroscience Centre, Toronto, Ontario, Canada
  3. 3Movement Disorders Clinic and the Edmond J. Safra Program in Parkinson's Disease, University Health Network, Toronto, Ontario, Canada
  4. 4Neurology Department, University of Florida, Gainesville, Florida, USA
  1. Correspondence to Dr Irene Litvan, Neuroscience Department, University of California San Diego, La Jolla, California, USA; ilitvan{at}ucsd.edu

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

We enjoyed reading the publication by Koga et al on ‘Neuropathology and emerging biomarkers in corticobasal syndrome’1 but would like to clarify their statement that ‘subsequent clinicopathological studies have shown that the sensitivity and specificity of the Armstrong criteria are suboptimal’. It is critical to emphasise …

View Full Text

Footnotes

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; internally peer reviewed.

Linked Articles